Is the Ramsay Health Care share price in the buy zone?

Is it time for investors to buy Ramsay Health Care Limited (ASX: RHC) with the share price just below its 52-week high?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Ramsay Health Care Limited (ASX: RHC) share price has been a strong performer over the last several weeks. Shares in the private hospital operator have risen 11% to $72.30 since the Federal election on 18 May, despite no market sensitive announcement being released since March.

Prior to the election, the Labor Party had announced a policy of putting a 2% cap on premium increases by private health insurers, which was priced into Ramsay's share price.

There were concerns that private health insurers would place additional pressure on private hospital operators such as Ramsay to lower prices in order to compensate for the capped premium increases. This would have materially impacted Ramsay's margins and future profitability. 

The election result has seen a reversal of fortunes in the sector, as business is expected to continue as usual moving forward. Similarly, investors have also become bullish on private health insurers such as Medibank Private Ltd (ASX: MPL) and NIB Holdings Limited (ASX: NHF), which have seen their share prices rise 20% and 32%, respectively, since the Federal election. 

Is this a return to double-digit earnings growth? 

Ramsay has guided for a soft FY19 by its own standards with management reaffirming core earnings per share growth of up to 2% including the Capio acquisition in February. The purchase of Capio is expected to be dilutive to earnings in FY19 and accretive within 2 or 3 years as Ramsay focuses on achieving synergies from the acquisition. 

The market is currently pricing in an acceleration in earnings growth for FY20, with the current earnings per share consensus for FY20 at $3.16. This would represent earnings growth of around 10% over the current FY19 consensus forecast of $2.87, and a return to the double-digit earnings growth that the company has delivered on a relatively consistent basis over the last decade. 

Foolish takeaway

For long-term shareholders, demand from the ageing population is expected to drive growth in the sector and Ramsay continues to maintain a market-leading position in Australia, which remains the largest contributor to group profitability. 

However, at 23 times forward earnings, shares in Ramsay are not cheap and a lot of bullishness is baked in at current prices. As a result, I would view Ramsay as a hold and would wait until the company updates the market on its expectations for FY20 before reassessing. 

Motley Fool contributor Tim Katavic owns shares of Ramsay Health Care Limited. The Motley Fool Australia has recommended NIB Holdings Limited and Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Has the Pro Medicus share price risen too high too quickly?

Pro Medicus shares have rocketed 173% since this time last year.

Read more »